ID
31314
Description
Study ID: 104574 Clinical Study ID: AR1104574 Study Title: A randomized blinded pilot trial of fondaparinux sodium (Arixtra®) versus unfractionated heparin in addition to standard therapy in a broad range of patients undergoing percutaneous coronary intervention (ASPIRE) Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 2 Study Recruitment Status: Completed Generic Name: fondaparinux sodium Trade Name: Arixtra Study Indication: Thromboembolism
Keywords
Versions (2)
- 8/13/18 8/13/18 -
- 8/13/18 8/13/18 -
Copyright Holder
GlaxoSmithKline
Uploaded on
August 13, 2018
DOI
To request one please log in.
License
Creative Commons BY-NC 3.0
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
Fondaparinux sodium (Arixtra) versus unfractionated heparin with patients undergoing PCI; Study ID: 104574
Similar models
Administrative Data
- StudyEvent: ODM
C2825181 (UMLS CUI [1,2])
C1300638 (UMLS CUI [1,3])
C2348585 (UMLS CUI [1,2])
C1301826 (UMLS CUI [1,2])
C1515258 (UMLS CUI [1,3])
C1549619 (UMLS CUI [1,4])